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AKTIVITI ANTI-MIKOBAKTERIA Labisia pumila. Benth. & Hook. f.  DAN
SEBATIAN BIOAKTIFNYA TERHADAP ORGANISMA PENGGANTI 
TUBERKULOSIS
ABSTRAK
Kemunculan strain tuberkulosis (TB) rintang pelbagai drug menjadi faktor 
utama yang menyumbang kepada peningkatan jangkitan TB secara global. Oleh yang 
demikian, keperluan yang mendesak bagi drug anti-TB yang efektif, selamat dan 
murah telah mendorong banyak kajian dijalankan terhadap produk semulajadi 
termasuk tumbuhan. Bahagian daripada Labisia pumila telah dikaji untuk mengenal 
pasti potensi anti-mikobakterianya terhadap organisma pengganti                
Mycobacterium tuberculosis (M. smegmatis, M. fortuitum dan M. kansasii) 
menggunakan asai pencairanmikro tetrazolium. Bahagian paling aktif telah 
dihasilkan oleh n-heksana batang-akar dan daun terhadap M. kansasii dengan 
kepekatan perencat minima (MIC) 50 - 200 μg/mL. Bahagian ini telah dipilih untuk 
proses fraksinasi berpandukan bioasai menggunakan teknik kromatografi turus yang 
telah menghasilkan 20 jenis fraksi yang berbeza. Fraksi ini telah diuji terhadap 
M. kansasii dan fraksi R2, R6 dan L7 telah  mempamerkan aktiviti paling 
memberangsangkan (MIC: 25 - 50 μg/mL). Ujian saringan lanjutan terhadap fraksi 
aktif ini telah dijalankan terhadap strain M. tuberculosis H37Ra dan nilai MIC yang 
dihasilkan masing – masing adalah 12.5, 50 dan 100 μg/mL. Analisis fitokimia 
terhadap fraksi paling aktif, R2 menggunakan komatografi gas-spektrometri jisim 
telah mengenalpasti tiga sebatian utama; asid vasenik, asid oktadekanoik dan               
asid 10-heptadesenoik. Aktiviti sebatian ini terhadap M. tuberculosis H37Ra telah 
xvi
mempamerkan nilai MIC 100 – 400 μg/mL, menunjukkan  aktiviti yang rendah 
berbanding fraksi asal R2 (MIC: 12.5 µg/mL). Kajian interaksi pecahan R2 dengan 
drug anti-TB barisan pertama terhadap M. kansasii dan M. tuberculosis H37Ra 
menggunakan kaedah papan catur telah menghasilkan satu interaksi sinergistik 
dengan rifampisin terhadap M. tuberculosis H37Ra dengan nilai indek kepekatan 
perencat fraksi (FICI) 0.375, aktiviti individu fraksi dan drug meningkat masing –
masing sebanyak lapan dan empat kali ganda. Interaksi sinergi ini diuji secara lanjut 
menggunakan kaedah masa membunuh dan telah menghasilkan interaksi tambahan 
dengan 94.46 % kadar pembunuhan pada akhir tempoh kajian. Pemerhatian terhadap
sel M. tuberculosis H37Ra yang dirawat dengan Fraksi R2 menggunakan mikroskop 
elektron tranmisi (TEM) menunjukkan pemecahan struktur sel luar dan perubahan 
bentuk sel tuberkel. Kajian kesitotoksikan Fraksi R2 terhadap warisan sel 
epitelium nasoforinks, NP69 menunjukkan ia amat sitotoksik dengan nilai IC50
sebanyak 7.57 ± 1.75 (purata ± SD) µg/mL. Kesimpulannya, aktiviti anti-
mikobakteria yang memberangsangkan oleh L. pumila menunjukkan potensinya 
sebagai sumber ubat untuk rawatan TB.
xvii
ANTI-MYCOBACTERIAL ACTIVITY OF Labisia pumila Benth & Hook. f. 
AND ITS BIOACTIVE CONSTITUENTS AGAINST SURROGATE 
TUBERCULOSIS ORGANISMS
ABSTRACT
The development of multidrug resistant tuberculosis (TB) strains becomes a 
major factor contributing to the rise of global TB incidence. Therefore, the urgent 
need of effective, safe and inexpensive anti-TB drugs has geared many researches 
towards natural products including plants. Partitions from Labisia pumila were 
investigated to evaluate their anti-mycobacterial potential against Mycobacterium 
tuberculosis surrogate organisms (M. smegmatis, M. fortuitum, and M. kansasii) 
using tetrazolium microdilution assay. The most active partitions were produced by 
n-hexane of stem-root and leaf parts against M. kansasii with minimum inhibitory 
concentrations (MICs) of 50 - 200 µg/mL. These partitions were selected for 
bioassay guided fractionation process using column chromatographic techniques, 
which produced 20 different fractions. These fractions were screened against 
M. kansasii and fractions R2, R6, and L7 exhibited the most promising activity 
(MIC: 25 – 50 µg/mL). Further screening of these active fractions was carried out 
against M. tuberculosis H37Ra strain and the MIC values produced were 12.5, 50 
and 100, µg/mL, respectively. Phytochemical analysis of the most active R2 fraction 
using gas chromatography-mass spectrometry resulted in the identification of three 
major compounds; vaccenic acid, octadecanoic acid, and 10-heptadecenoic acid. The 
activity of these compounds against M. tuberculosis H37Ra exhibited MIC values 
100 - 400 µg/mL, displaying lower activity compared to their original fraction R2 
xviii
(MIC: 12.5 µg/mL). Interaction study of R2 fraction with first-line anti-TB drugs 
against M. kansasii and M. tuberculosis H37Ra using checkerboard method produced 
one synergistic interaction with rifampicin against M. tuberculosis H37Ra, with 
fractional inhibitory concentration index (FICI) value of 0.375, increasing the 
individual activity of fraction and drug by eight and four folds, respectively.  This 
synergistic interaction was further verified using time-kill assay and produced an 
additive interaction of 94.46 % killing rate at the end of the study period. The 
observation of M. tuberculosis H37Ra cells treated with R2 fraction using 
transmission electron microscopy (TEM) showed the breakage of the outer cell 
structure and deformation of the tubercle cells. Cytotoxicity study of R2 fraction 
against nasopharyngeal epithelial cell line, NP69 revealed that it was highly 
cytotoxic with IC50 value of 7.57 ± 1.75 (mean ± SD) µg/mL. In conclusion, the 
promising anti-mycobacterial activity of L. pumila indicates its potential as a source 
of remedy for the treatment of TB.
1CHAPTER 1
INTRODUCTION
1.1 General introduction
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) 
remains one of the most common infectious pathogens of mankind that infects one 
third of the world’s population (Stewart et al., 2003). M. tuberculosis usually infects 
the lungs (pulmonary TB) and can disseminate to other sites of the body 
(extrapulmonary TB). These bacteria can also remain dormant in the body for years 
asymptomatically before causing active infection. Now, TB infection becomes a new 
leading cause of death globally together with human immunodeficiency virus (HIV). 
The World Health Organization (WHO) estimated that, there were 1.2 million deaths 
and 9.6 million people became sick with TB worldwide in 2014 (WHO, 2015a). Out 
of these estimates, six million were new TB cases and about 480,000 cases of 
multidrug-resistant TB (MDR-TB).
The global emergence of MDR-TB and extensively drug-resistant TB   
(XDR-TB) strains becomes a serious threat to human health (de Araujo-Filho et al.,
2008). The percentage of patients infected with TB that cannot be cured with current 
therapeutic regimen is increasing annually. Unfortunately, there have been no new 
drugs being developed against TB since the 1960s (Todar, 2004). These limited 
discoveries of new drugs from natural and synthetic compounds are mainly caused 
by the slow growth rate, biosafety concern and other issues that are related to 
Mycobacterium species (Primm & Franzblau, 2007). Therefore, urgent actions must 
be taken in order to combat this disease, including antibiotic control usage, 
continuous research on the genetic mechanisms of the bacterial resistance and 
2development of new drugs, either synthetic or from natural products (Nascimento             
et al., 2000).  
Nowadays, studies based on the extraction of biologically active compounds 
from plant species for medicinal purpose are becoming prominent. Natural products 
from plants contain a wide range of substances and continue to play significant role 
in drug discovery and development (Alam et al., 2009). About 80 % of the world’s 
population rely on the use of traditional medicine, which are predominantly plant 
based (Obeidat et al., 2012). There are more than 100 plant species in Malaysia 
reported to have medicinal properties as remedies in the treatment of human diseases 
and some microbial infections (Perumal et al., 2012). One famous plant is Labisia 
pumila (Benth).  
L. pumila is commonly known as Kacip Fatimah in Malaysia. It belongs to 
the Mysinaceae family. It is a small sub-herbaceous plant with leafy appearances that 
can be found mainly in the low land and hill forest of Malaysia and Indonesia 
(Shahrim et al., 2006). Almost all parts of L. pumila are used in folk medicine. It is 
commonly used to induce childbirth, ease the pain of delivery, and to treat a variety 
of illnesses including dysentery, flatulence, rheumatism, gonorrhoea and 
dysmenorrhoea (Ibrahim & Jaafar, 2011). Extracts from L. pumila have been shown 
to possess inhibitory activity against many aerobic microorganisms (Karimi et al., 
2011). However, there is limited finding based on scientific research to claim the 
anti-mycobacterial activities of this plant. In a recent study, Mohamad (2014) 
observed that the non-polar n-hexane partition of root and leaf parts of L. pumila
exhibited promising anti-TB activity (MIC: 50 µg/mL and 100 µg/mL, respectively) 
against M. tuberculosis H37Rv, which was worthy of further investigation. 
Therefore, based on the approach “follow-up of anti-microbial activity reports”, the 
3main aim of this study was to further investigate the anti-mycobacterial activity of 
this plant against non-pathogenic surrogate TB organisms, M. smegmatis,                          
M. fortuitum, M. kansasii, and M. tuberculosis H37Ra. This study opted for use of 
surrogate organisms, since M. tuberculosis H37Rv is a virulent strain and requires 
strict containment facilities for its handling. In order to achieve the main objective of 
this study several key activities were undertaken including the identification of the 
active chemical constituents, their interactions with anti-TB drugs, and their 
cytotoxicity studies.
1.2 Aim and objectives of research
The main purpose of this study was to investigate the anti-mycobacterial 
property of L. pumila using surrogate TB organisms. The specific objectives were: 
1. To screen the anti-mycobacterial activities of L. pumila partitions against test 
Mycobacterium species using a colorimetric tetrazolium microplate assay 
(TEMA) and to identify the bioactive fractions using bioassay-guided 
chromatographic fractionation techniques. 
2. To identify the phytochemical constituents of the most active fractions by 
using gas chromatography–mass spectrometry (GC–MS) and to determine 
their anti-mycobacterial inhibition.
3. To study the interaction activity of the most active fraction with first-line 
anti-TB drugs using checkerboard and time-kill methods against M. kansasii
and M. tuberculosis H37Ra.
4. To study the effects of the most active fraction on the ultra-structure of the 
test organism under transmission electron microscope (TEM) and to 
investigate their cytotoxicity levels using nasopharyngeal epithelial cell line.
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Tuberculosis 
2.1.1 Overview 
Tuberculosis is a serious respiratory disease, which is a major cause of 
morbidity and mortality worldwide (Chakrabarti et al., 2007). The causative agent of 
TB, M. tuberculosis was first isolated by Robert Koch in 1882 (Cambau & 
Drancourt, 2014). This contagious disease can be transmitted by airborne particles 
from throat and lung droplets of active infected person to anyone nearby. Only a few 
small droplets nuclei containing these bacilli are required for a person to become 
infected. The inhalation of the tubercle bacilli may lead to one of these possible 
effects: a) immediate elimination of bacilli, b) latent infection, c) development of 
primary disease, and d) reactivation of disease after many years of infection (Robert 
& Wani, 2013).   
TB infection can be classified into pulmonary TB (PTB) and extra pulmonary 
TB (EPTB) (Sharma & Mohan, 2004). PTB commonly affects the lungs and is a 
highly contagious disease. The infected patients with active PTB may undergo 
asymptomatic disease, mild or progressive cough, or develop several common 
symptoms such as fatigue, fever, chill, coughing with bloody sputum, night sweats, 
and loss of appetite and weight (Crane, 2013). Unlike PTB infection, EPTB occurs in 
organs other than the lungs and is usually not infectious. The common sites of EPTB 
infection include lymph nodes, osteoarticular areas, pleura, and bones meninges 
(Golden, 2005). The infection of EPTB has become more prevalent in patients with 
HIV infection. The symptoms of EPTB vary by site of infection, but commonly 
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include abdominal pain, confusion, seizures, and persistently swollen gland and 
headache (Rieder et al., 1990, National Health Service (NHS), 2014).   
The infection of M. tuberculosis commonly results in either latent infection or 
active TB infection. In latent TB infection, the infected persons do not develop any 
clinical signs or symptoms and are not contagious to others. The latency period 
signifies the majority of infected individuals in a state, in which the host manage to 
control the infection from developing inside the body (Lin & Flynn, 2010). Once the 
immune system of infected persons fails in some ways, the reactivation of TB occurs, 
resulting in the spread of this contagious pathogen (WHO, 2009a). The uncontrolled 
misused and mismanagement of drug treatment can result in the development of 
drug-resistant TB. The emergence of MDR-TB and XDR-TB has further become a 
serious threat to the global public health (Centres for Disease Control and Prevention 
(CDC), 2015).   
 
2.1.2 Epidemiology of tuberculosis  
Epidemiology study of TB is crucial for effective measure in controlling the 
complexity of disease outbreak. TB is declared as a major cause of death around the 
globe and becomes a global health burden. According to Global Tuberculosis report 
(2015), in 2014, there were 9.6 million new TB cases, with 1.5 million deaths 
inclusive of 1.1 million among HIV-negative people and 0.4 million among                  
HIV-positive people (WHO, 2015a). From these values, over 95 % of the death cases 
occur in low and middle income countries. Globally, the largest burden of TB with 
58 % of new cases occurred in the South East Asian and Western Pacific regions 
(Figure 2.1). African region accounted for the highest TB burden, with 281 cases for 
every 100,000 population compared  to global average   of  133  cases. These  reports  
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Figure 2.1. Estimated global TB incidence rate, 2014. 
(WHO, 2015a) 
 
also estimated that over one million children became sick and 140,000 children died 
of TB. In addition, almost 480,000 people who developed MDR-TB were reported 
worldwide. The latest report in 2015 showed that the statistic of death ratio among 
TB co-infection with HIV positive patients was 1 in every 3 deaths, making TB as 
one of the leading killers among the HIV patients (WHO, 2015a). 
In Malaysia, an estimated number of 2400 deaths caused by TB infection, 
excluding co-infection with HIV patients were reported in 2014 (WHO 2015a). 
Approximately 78,000 cases of all form of TB were notified and 24,054 new TB 
cases and relapse were reported (Table 2.1). 
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Table 2.1. Estimated TB burden in Malaysia, 2014. 
(WHO, 2015a) 
 
Population 2014 30 million  
Estimates of TB burden *2014 Number (thousand) Rate (per 100 000 population 
Mortality (excludes HIV + TB) 24 (1.3-3.7) 8 (4.5-12) 
Mortality (HIV + TB only) 0.63 (0.38-0.93) 2.1 (1.3-3.1) 
Prevalence (includes HIV +TB) 40 (19-69) 135 (63-232) 
Incidence (includes HIV + TB) 31 (25-37) 103 (83-124) 
Incidence (HIV + TB only) 22 (1.8-2.6) 7.3 (5.9-8.8) 
Case detection, all form 78 (65-96) 
Estimates of MDR-TB butden *2014 New Retreatment 
% of TB cases with MDR-TB 0.4 (0.24-0.63) 1.1 (0.24-0.33) 
MDR-TB case among notified pulmonary TB cases 80 (48-120) 20 (4-56) 
TB case notification 2014 New** Relapse 
Pulmonary, bacteriologically confirmed  14099 749 
Pulmonary, clinically diagnosed 5743 300 
Extrapulmonary  3055 108 
Total new and relapse  24054 
Previously treated, excluding relapse 657 
Total case notified 24711 
Among 24 054 new and relapse cases:  
691 (3%) cases aged under 15 years; male:female: 1: 7 
 
 
 
2.1.3 The tubercle bacteria 
Mycobacterium species belong to the family of Mycobacteriaceae and was 
first discovered by Hansen in 1868, who isolated M. leprae and followed by Robert 
Koch in 1882, who isolated M. tuberculosis (Cambau & Drancourt, 2014).                       
M. tuberculosis is a non-motile, rod-shaped, slow-growing and facultative 
intracellular pathogen, which can survive and thrive in the host’s macrophages for a 
long period and under different stress conditions. Under favourable condition, the 
generation time of M. tuberculosis is between 18 - 24 hours and produces white to 
light-yellow colony within 3 - 4 weeks on media plates (Gengenbarcher & 
Kaufmann, 2012).   
The term ‘myco’ means fungus to illustrate the characteristics of 
mycobacteria that grow in mould-like fashion in liquid culture media (James, 1994). 
The growth features of mycobacteria are significantly different compared to other 
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bacteria species, which are probably influenced by their highly packed hydrophobic 
cell wall. The cell wall structures are divided into inner and outer layers that 
surround the plasma membrane, which make up a rigid cell wall. The outer layer 
compartments consist of mainly proteins and lipids component, which are freely 
linked with the cell wall (Brennan & Nikaido. 1995; Draper, 1998). 
The inner compartments are divided into three components; peptidoglycan 
(PG), arabinogalactan (AG), and mycolic acids (MAs), which are covalently linked 
together to form mycolyl-arabinogalactan-peptidoglycan complex (MAPc). These 
components are arranged accordingly starting from PG and ending with MAs, which 
surround the plasma membrane (Brennan, 2003). Figures 2.2 illustrates the structural 
model of the mycobacterial cell wall. PG or murein, is a polymer that consists of 
peptides and glycan strands attached to the plasma membrane. PG forms a rigid 
skeletal backbone of the cell envelope by maintaining the cell shape and thus, 
protects the cell from osmotic pressure. AG is made up of biopolymer 
polysaccharides, which consist of arabinose and galactose monosaccharaides. AG 
helps in maintaining the cell wall integrity and acts as an attachment site for MAs 
and peptidoglycan by covalent bonding. MAs are long chain fatty acid, which may 
represent up to 40 % of the cell dry mass (Crick et al., 2001). The structures are 
arranged compactly as monolayer and consist of aliphatic side chain at the position 
C2 and high molecular weight of 3-hydroxy fatty acid. The molecular mass of 
mycolic acids of mycobacterial varies from C60 to C90 (Dworkin & Falkow, 2006). 
The special constituents of mycolic acids affect the permeability of the cell surface, 
which contributes to the hydrophobic nature of the cell wall. These characteristics 
also contribute to its distinctive property of acid fastness due to their impermeability 
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by certain dyes and stains such as Gram staining and required special staining 
method of the Ziehl-Neelsen (Daffe & Reyrat, 2008). 
 
 
 
Figure 2.2.  Structural model of the mycobacterial cell wall. 
 (Rolfe, 2015)  
 
2.1.4 Pathophysiology of tuberculosis 
The progression of the disease depends mainly on prior exposure, type of 
strain, vaccination, infectious dose, and the immune system of the host (Todar, 
2004). The inhalation of droplets containing tubercle cells may or may not cause the 
infected person to develop the clinical symptoms (Table 2.2). Basically, the TB 
infected persons may encounter several possible outcomes including: a) immediate 
destroyal of TB bacilli by the host’s primary immune system responses, b) the 
development of active TB, probably by a person with lack of ability to control the 
infection, and c) development of latent stage infection (Flynn & Chan, 2001).   
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Table 2.2.  The similarities and differences of tuberculosis infection and disease. 
(Todar, 2004) 
 
Tuberculosis infection Tuberculosis disease in lungs 
M. tuberculosis present M. tuberculosis present 
Tuberculin skin test positive Tuberculin skin test positive 
Chest X-ray normal Chest X-ray usually reveals lesion 
Sputum smears and cultures negative Sputum smears and cultures positive 
No symptoms 
Symptoms such as cough, fever, weight 
loss 
Not infectious Often infectious before treatment 
Not defined as a case of TB Defined as a case of TB 
 
Initially, after inhalation of airborne droplet nuclei, the infection of                       
M. tuberculosis occurs in an alveolar macrophage where the replication occurs 
(American Thoracic Society (ATS), 2000; Frieden et al., 2003). This replication 
triggers the cytokine formation and thus, initiates the production of inflammatory 
response. In response, host’s macrophages and lymphocytes migrate to the infection 
site and form granulomas to prevent further dissemination of M. tuberculosis to other 
organs. The formation of granuloma also helps to establish direct immune reaction at 
the site of infection. At this stage, the granulomatous lesion consists of                                
M. tuberculosis, which is in inactive state and remains dormant for some time 
(Knechel, 2009).  
M. tuberculosis can exist in different states during infection (Nguta et al., 
2015). The different states describe the ability of M. tuberculosis to survive in host’s 
primary immune cell for a long period and under different stress conditions. The 
latency period or latent TB infection (LTBI) is a condition when the infected person 
with TB does not produced any symptoms or disease. The inactive TB infection 
occurs in the early stage of infection when the host’s cell-mediated immune response 
protects and limits the progression and dissemination of M. tuberculosis. In addition, 
the triggered host’s immune also help in latency period of infection and sustaining 
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the long term immune protection (Ewer et al., 2006). The treatment for LTBI is slow 
and challenging to accomplish. Without suitable prescription, the risk of progression 
from LTBI to active symptomatic TB infection will increase. The reactivation of 
LTBI occurs after several years or decades after subclinical infection. About 10 % of 
people infected with LTBI will develop the active TB in their life time (WHO, 
2015a). However, the risk of activation is higher in immunocompromised patients 
with co-infection with HIV/acquired immunodeficiency syndrome (AIDS), diabetes, 
obesity, and chronic inflammatory disease (Barry et al., 2009). Active pulmonary TB 
occurs when the M. tuberculosis is able to overcome the immune response and 
begins to multiply and spread, resulting in the development of the symptomatic TB 
(CDC, 2016). 
 
2.1.5 Diagnosis of tuberculosis 
According to WHO, it is estimated that 43 million lives were saved from 
successful TB diagnosis and treatment between 2000 and 2014 (WHO, 2015a). The 
selection of suitable diagnosis for TB infection should include the purpose for 
testing, overall cost, effectiveness of examination, and test availability (CDC, 
2012a). A complete diagnosis for TB infection includes medical history, chest 
radiograph, physical examination, tuberculin skin test, diagnostic microbiology tests, 
and serological tests (Jeong & Lee, 2008).  
The information about the medical history of the infected patients helps the 
clinicians to specify a suitable diagnosis, depending on the type of TB suspected.  
The history includes: a) prolong symptoms of active TB, e. g. cough, fatigue,  chest 
pain, fever, or night sweats; b) recent exposure with a person who might be infected 
with TB; c) recent travel to high-incidence countries; d) medical condition, e. g. HIV 
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infection, e) demographic factors, e. g. occupation, age, ethnic or country of origin, 
and f) past TB history (National Institute for Health and Clinical Excellence (NICE), 
2011; WebMD, 2014).      
A physical examination provides useful information about the overall 
condition of the patient and helps to identify the disease progression that may 
determine the TB treatment plan. Chest radiography is an essential diagnosis method 
to identify the possibility of pulmonary TB infection. Radiographic of posterior and 
anterior segment of the lungs is used to identify chest abnormalities related to TB 
infection (Leung, 1999). These abnormality changes are usually associated with 
reactivation of TB infection, which causes fibronodular infilterate, specifically in the 
upper posterior parts of the lungs. However, the radiographic abnormalities of 
primary TB infection are more difficult to distinguish from other pulmonary 
infections (Wilkins et al., 2007). Although abnormalities are detected on chest 
radiography, these results may suggest TB infection, but not as a confirmation of the 
disease. Thus, chest radiographs may be important to detect the probability of 
pulmonary TB infection, especially in a person with positive reaction towards 
tuberculin skin test with asymptomatic TB (CDC, 2011). 
The Mantoux tuberculin skin test (TST) is the standard method that is used 
widely for the detection of LTBI (Nayak & Acharjya, 2012). This method involves 
the intracutaneous injection of purified protein derivatives (PPD) into inner part of 
the arm. The reaction is measured in millimetres of the induration, which involves 
visible raised, hardened area or swelling after 48 - 72 hours of administration. The 
size of induction between 5 – 15 mm is classified as a positive result, which indicates 
TB infection (CDC, 2012b).   
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Diagnostic microbiological tests of TB diagnosis are necessary to detect the 
presence of acid-fast-bacilli (AFB) from sputum smear and other specimens 
(Mathew et al., 2012). The microbiological testing of TB involves the isolation, 
detection and identification of mycobacteria species, type of drug resistance, and 
observation after prescription. Even though acid-fast microscopy is relatively a rapid 
and easy method, it is not specific because the results produced are unable to 
distinguish between MTB and non-tuberculous strain (Hale et al., 2001).  
New advanced serological and molecular diagnostic techniques for TB 
detection include polymerase chain reaction (PCR) and interferon-gamma release 
assays (IGRAs). In PCR assay, nucleic acid of infected patients are amplified and 
used to distinguish between M. tuberculosis and other mycobacteria strains based on 
their genetic information (Knechel, 2009). Meanwhile, in IGRAs, whole-blood tests 
from infected patients are used to determine the immune reactivity towards                     
M. tuberculosis (CDC, 2012a). 
 
2.1.6 Treatment and prevention of tuberculosis 
Mycobacterium tuberculosis remains a major cause of infectious disease 
worldwide although chemotherapy and vaccination are available as control measures. 
An estimated 47 % of TB death rates dropped between 1990 and 2015 (WHO, 
2015a). The standard treatment for TB infection requires multiple drugs treatment, 
which consists of several antibiotics in fixed-dose combination. The multiple drug 
therapy is important to prevent the development of drug-resistant mutants that might 
occur during the treatment period. In addition, multiple drug therapy is able to 
increase the bactericidal effect and also reduce the toxicity level of drugs by lowering 
the drug consumption dosage (Blomberg et al., 2001).   
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Treatment regimen for new TB patients with drug susceptible TB requires an 
intensive initial phase of two months, which consists of isoniazid (INH), rifampicin 
(RIF), pyrazinamide (PZA), and ethambutol (EMB) followed by a continuation 
phase of INH and RIF of either four or  seven months. Once the drug susceptibility 
test is known and fully susceptible, EMB can be excluded from the continuation 
phase (Morbidity and Mortality Weekly Report (MMWR), 2003; WHO, 2009b). 
However, a more complex and longer treatment period are needed to manage 
resistant strains of MDR-TB and XDR-TB (Gupta & Bakhta, 2012). MDR-TB 
strains are resistant to RIF and INH while XDR-TB strains have additional resistance 
to any ﬂuoroquinolones and to at least one of the three injectable second-line anti-TB 
drugs (amikacin, kanamycin, or capreomycin) (Youm & Saier, 2012). 
A successful treatment is important in the effort to control and manage TB. 
Effective vaccination strategy is needed to prevent incidence of TB. The invention of 
TB vaccine in 1921 called bacille Calmette-Guérin (BCG) may help in preventing 
severe TB infection in children. However, BCG is unable to protect adults from TB 
infection especially against pulmonary TB (Barreto et al., 2006). Therefore, there is 
an urgent need for new vaccine, which is safer and effective to protect against all 
forms of TB including infection, disease, and relapse (Tiwari et al., 2011). Until 
recently, 16 different new TB vaccine candidates are now in clinical trials and 
preclinical development (WHO, 2015b). These vaccines were generated from whole 
cell mycobacteria and various subunits of M. tuberculosis antigens, which are 
expressed as recombinant proteins. 
 
 
 
15 
 
2.2 Natural products as source of therapeutic agents 
Plants and herbs are the earliest sources of medicine and have been used for 
thousands of years with great contributions as therapeutic properties. In Asian 
countries, the traditional therapies include ayurvedic medicine (India), traditional 
chinese medicine, jamu (Indonesia), korean chinese medicine and japanese medicine 
(kampo) (Itokawa et al., 2009). According to WHO, it is estimated that 80 % of some 
Asian and African countries depend on traditional medicine as primary health care, 
while in developed countries, the traditional medicine is used as alternative or 
complementary medicine (WHO, 2008).   
There are many reasons for using plants as natural source of therapeutic 
agents, which include a) as herbal remedy by using whole or part of plant, e.g. garlic; 
b) as direct drug usage by isolation of bioactive compounds, e.g. morphine, digoxin; 
c) as lead compounds for designing of semi-synthetic drugs, which produce 
patentable drugs with lower toxicity and/or higher activity from bioactive 
compounds of novel or known compounds structures, e.g., metformin, nabilone; and 
d) as pharmacologic tools agents, e.g., mescaline lysergic acid diethylamide (Daniel 
et al., 2001). The common advantages of using medicines derived from plant product 
are because they are safer than other synthetics prescription, more economical and 
cover wider therapeutic benefits. 
Plant derived medicines offer great contribution towards human health. The 
abundant distributions of plant diversity especially higher plant in tropical countries 
provide most of these therapeutics agents (Owolabi et al., 2007). The presence of 
secondary metabolites such as, flavonoids, tannins, terpenoids, and alkaloids are the 
most important active substances with anti-microbial properties (Obeidat et al., 
2012). These substances are believed to act as constitutive chemical barriers of plant 
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defence mechanism against herbivores and insects or even protect the plants from 
microbial attack and other inducible anti-microbials (Cowan, 1999). Plant based                
anti-microbial property becomes the most important target source for new drug 
development. However, further research of their therapeutic potential needs to be 
carried out to identify their benefits and side effects. The multiple reactions from 
plant therapeutics on the human body should be investigated before using any plant 
as treatment. This is mainly due to the multiple actions of plant metabolites, which 
usually react beyond the treatment of diseases (Iwu et al., 1990).   
Based on several studies, therapeutic value of ethnobotanical plants regains 
much interest in many researches to identify and isolate natural compounds that 
exhibit certain activity against mycobacteria (Jimenez-Arellanes et al., 2003; Ramos 
et al., 2008; Gupta et al., 2010). In a previous study, selected Malaysian plants that 
are traditionally used to treat respiratory diseases and symptoms of TB were screened 
to investigate their therapeutics property against M. tuberculosis (Mohamad et al., 
2011). The results of this study showed that 36 local plants exhibited promising            
anti-TB activity against M. tuberculosis H37Rv. This research has provided a good 
TB database of Malaysian plants that can be selected for further phytochemical and 
pharmacological investigations.  
 
2.3 Labisia pumila as a therapeutic plant 
2.3.1 Botanical characteristics 
Labisia pumila (Benth) or locally known as Kacip Fatimah (Figure 2.3) is a 
small herbaceous and slow growing creeping rhizome herb. L. pumila belongs to the 
family of Myrsinaceae, which consists of 30 genera and 1000 species and about 40 
species are used in medical field in  Asia-Pacific region  especially  for  treatment  of  
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Figure 2.3. Labisia pumila (a) whole plant, (b) flowers, and (c) fruits. 
Forest Research Institute Malaysia (FRIM), (2012) 
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inflammatory ailments (Shah et al., 2011). It can be found widely in the lowland and 
shady areas of forest floors in South East Asian countries. 
 There are three varieties of L. pumila documented in Malaysia, i.e. L. pumila 
var. alata, L. pumila var. pumila, and L. pumila var. lanceolata (Stone, 1998). 
Different varieties of L. pumila have different petiole and leaf structures (Sunarno, 
2005). L. pumila var. pumila has slightly marginated petiole with ovate leaf blade 
structure, which is broad rounded at the base and tapered pointed towards the tip. In 
addition, it has lighter green colour on the abxial surface and dark green colour on 
adaxial surface. L. pumila var. alata has broadly winged petiole with distinctive red 
veins and L. pumila var. lanceolata has long lanceolate leaf shape with terete petiole 
characteristics (Abdullah et al., 2013). 
 
2.3.2 Traditional therapeutic uses 
Labisia pumila has been widely used by ethnic Malay women to treat many 
ailments and also for health supplements (Hussain & Kadir, 2013). A water 
decoction is normally prepared by boiling the leave, root, or all plant parts in plain 
water, and is consumed as a tonic. L. pumila is also consumed to induce and ease the 
pain of delivery, as a post-partum medication to contract the birth channel and to 
regain body strength, help to delay fertility, regulate normal menstrual cycle and to 
prevent menopausal symptoms. Some other folkloric uses include, treating a variety 
of illnesses such as dysentery, flatulence, rheumatism, gonorrhoea, dysmenorrhoea, 
and “sickness in the bones” (Jamal et al., 2003; Ibrahim & Jaafar, 2011). This plant 
is also used for firming and toning the abdominal muscles and to relieve stomach 
discomfort of babies by rubbing the abdomen with the leaf and coconut oil paste 
(Bodeker et al., 2009).   
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2.3.3 Phytochemical contents 
Labisia pumila has been reported to contain high levels of bioactive 
compounds including alkyl compounds, saponins, flavonoids, benzoquinone 
derivatives, isoflavonoid, and phenolics acids (Abdullah et al., 2013). These 
bioactive phytochemical contents are responsible towards its wide range of 
pharmacological activities and medical values. The flavonoid and phenolic contents 
were reported to be higher in the leaves compared to the other plant parts (Abdullah 
et al., 2013). 
Various flavonoids and phenolic acids are scientifically proven for its            
anti-oxidative potentials that can protect body cells from free radical effects of 
reactive oxygen species (Ali & Khan, 2011; Chua et al., 2011).  If the anti-oxidant 
content is imbalanced, the excessive amount of free radicals will enhance the cellular 
damage of the body that can develop into many diseases such as, autoimmune 
diseases, inflammation, cancer, arteriosclerosis, cataract, Parkinson’s disease, and 
aging (Kukic et al., 2006). The anti-oxidant properties of these compounds have been 
reported to be higher than vitamin C, E and carotenoids (Tsao & Deng, 2004; Dai & 
Mumper, 2010). The anti-oxidant activities from flavonoids also provide important 
protection against ultra-violet (UV) irradiation that might affect the human dermal 
fibroblasts (Norhaiza et al., 2009; Avula et al., 2011). The saponins contents can be 
found in many parts of the plant including root, leaves, fruits, and stems, which are 
specifically higher in stem and root parts (Abdullah et al., 2013). Saponin 
compounds have been reported to be good chemopreventive agents that act as                 
anti-neoplastic, anti-bacterial, and anti-cancer (Laszczyk, 2009).  
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2.3.4 Pharmacological activities 
Previous studies on the activity of methanolic extracts from different varieties 
of L. pumila have shown that the extracts possess active anti-bacterial activity at low 
concentration against Gram-positive and Gram-negative bacteria (Karimi et al., 
2013). However, these plant extracts showed moderate anti-fungal activity. In 
addition, the same group of researchers also reported the potential in vitro effects of 
three different varieties of L. pumila as anti-inflammatory, anti-cancer and cytotoxic 
effects by using microwave extraction method at different extract concentrations. 
L. pumila was also shown to exert phytoestrogen (plant estrogen) property 
that can be used as an alternative treatment for estrogen replacement theraphy (ERT) 
(Lelovas et al., 2008). The combining effects of L. pumila as anti-inflammatory, 
phytoestrogenic, and anti-oxidative properties help to overcome the estrogen 
deficiency problem and thus, it will prevent development of postmenopausal 
osteoporosis (Nadia et al., 2012).  
  
2.4 Strategies for anti-tuberculosis drug development from plants 
2.4.1 Target organisms 
The development of new anti-TB drugs requires a high-throughput screening 
procedure, which is comprehensive and much easier to carry out. Ideally, the test 
organism should be the etiological agent itself. However, the use of virulent strain of        
M. tuberculosis as the test organism is highly dangerous because it is highly 
infectious in nature. Hence, the handling of M. tuberculosis virulent strain requires a 
complex and strict containment facility and this poses a major obstacle towards drugs 
development because many non-clinical laboratories do not have such facilities 
(Griffths et al., 1998). This has led to the search of suitable candidate organism as a 
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‘surrogate’, which can be used as an alternative to substitute the target organism 
based on its ideal attributes and genetic profiles. In the scope of surrogate TB 
organisms, the surrogate organisms should be non-virulent strains and safer to handle 
in biosafety level 2, less hazardous, and more practical for primary screening of 
inhibitors in early development stages of drug development. The common TB 
surrogates include M. smegmatis, M. fortuitum, M. kansasii and M. tuberculosis 
H37Ra (Gupta & Bhakta, 2012; Ibekwe & Ameh, 2014). 
 
Mycobacterium smegmatis 
Mycobacterium smegmatis is a unicellular, non-motile and rod shaped 
bacterium with thick hydrophobic cell wall (Sattar, 2007). M. smegmatis can be 
found in normal human-genital secretions, and also in animal and environments such 
as, soil, water and plants (Newton et al., 1993). The pathogenicity related to             
M. smegmatis only occurs in patients with weak immune system (Pennekamp et al., 
1997). Thus, M. smegmatis is classified as non-pathogenic and also a fast growing 
mycobacteria as its generation time is about three hours under favourable conditions. 
M. smegmatis has been used widely as a model organism to study the basic cellular 
pattern and physiology process of other pathogenic Mycobacterium species such as 
M. tuberculosis, M. leprae, and M. paratuberculosis (Provvedi et al., 2008).                    
M. smegmatis is also widely used to study the genetic analysis of M. tuberculosis due 
to its ability to grow rapidly and ease of growth and cultivation (Jacobs, 2000).  The 
natural resistance of M. smegmatis towards INH and RIF was reported to be identical 
to MDR-TB strain from clinical isolates with similar sensitivity profile (Wallace et 
al., 1988; Li et al., 2004). M. smegmatis is also commonly used as a primary screen 
to select active compounds, which could be active against M. tuberculosis (Lu & 
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Drlica, 2003; Andries et al., 2005). Furthermore, the close related protein expression 
and biosynthetic pathway with other related Mycobacterium species especially                
M. tuberculosis, makes M. smegmatis a good surrogate to study the behavioural 
properties of other Mycobacterium species (Chaturvedi et al., 2007).   
 
Mycobacterium fortuitum 
Mycobacterium fortuitum is a rapid to moderate growing nontuberculous 
mycobacteria, which are classified in the Runyon group IV and can be found widely 
in water, soil and dust environment (Choi et al., 1993). M. fortuitum produces               
non-pigmented colonies with three to four hours generation time. M. fortuitum is an 
opportunistic mycobacteria that can cause lung disease resembling TB, 
lymphadenitis, soft skin and joint infection, catheter infections, eye disease after 
trauma, and disseminated infection in severe immosuppression, especially in HIV 
patients (Mary et al., 2006). According to previous studies, M. fortuitum had been 
used widely as surrogate organism based on the good correlations shown between   
M. fortuitum and MTB in susceptibility testing (O’Donnell & Gibbons, 2007; Andrea 
et al., 2009). In addition, M. fortuitum is usually susceptible towards commonly used 
anti-TB drugs.  The rapid growing of M. fortuitum allows the test to be accomplished 
in a short time (Stephen et al., 2005).  
 
Mycobacterium kansasii 
Mycobacterium kansasii is a slow growing nontuberculous 
photochromogenic mycobacteria with doubling time is about one day, and classified 
in a Runyon class I, which produces yellow-orange colonies when exposed to light 
and dark red crystals of β-carotene colonies when grown in light incubator or 
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prolonged exposure to light source (Parija, 2012; Huitt et al., 2015). M. kansasii can 
cause serious opportunistic infection and is categorized as one of the most common 
opportunistic nontuberculous mycobacteria causing lung pulmonary infection 
resembling TB (Bloch et al., 1998). M. kansasii can also cause osteomyelitis, 
arthritis, dermatitis, cervical lymphadenitis, and disseminated infection, which are 
usually related to immunosuppressed patients (Sherer et al., 1986; Valainis et al., 
1991).  The isolates of M. kansasii are susceptible to RIF, INH, streptomycin (STR), 
EMB, rifabutin (RFB), amikacin (AMK), ethionamide (ETH), clarithromycin (CLR) 
and ciprofloxacin (CIP) (Shitrit et al., 2007). Although M. kansasii can spread by 
aerosol route, the infection is not transmitted by direct contact from person-to-person 
because it only can be found in water or soil environment and the major reservoir for 
M. kansasii is the tap water (Evans et al., 1996).  
 
Mycobacterium tuberculosis H37Ra 
Mycobacterium tuberculosis H37Ra strain is an attenuated tubercle bacillus, 
which originated from the parental virulent strain of M. tuberculosis H37 (Steenken 
et al., 1934). This slow growing avirulent strain has a generation time of between            
18 - 24 hours and is classified as Biosafety Level 2 (BSL) organism (Gengenbarcher 
& Kaufmann, 2012). Even though the variance in virulence between strain H37Ra 
and H37Rv are still being debated, several data have reported the differences in 
characteristics between the strains H37Ra and H37Rv, including the ability of strain 
H37Ra to form raised colony morphology (Steenken, 1934), reduced ability to 
survive under anaerobic condition or inside the macrophage (Heplar et al., 1954), 
unable to form cord formation (Middlebrook et al., 1947), loss ability to interrupt 
phagosomal membranes (Hart & Armstrong, 1974), and avirulent in guinea pig and 
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mice (Steenken, 1938). The genomic differences between H37Rv and H37Ra, which 
involved gene insertions, deletions, and single nucleotide polymorphisms have been 
reported previously. Zheng et al. (2008) reported that 57 of different genetic 
variations, which may account to its pathogenicity differences and other phenotypic 
changes from virulent strain of H37Rv were identified. However, Malen et al.  
(2011) observed that the similar relative abundance of the proteins was identified in 
both strains and suggested that the two strains are highly related at protein level. 
Thus, H37Ra strain is widely used as an alternative strain to replace the virulent 
strain of H37Rv also due to other factors, including similar slow growing pattern, 
non-pathogenic and more correlated with H37Rv strain compared to other rapid 
growing mycobacteria (Nguta et al., 2015). Moreover, the close relation between 
H37Ra with H37Rv in terms of genetic composition and drug susceptibility profile 
makes M. tuberculosis H37Ra the best alternative option in less equipped 
laboratories (Ibekwe & Ameh, 2014).    
 
2.4.2 Bioassays for in vitro evaluation of anti-tubercular activity 
             The emergence of resistant strains together with complicated and long course 
regimens increases the urgent need for new therapeutics against TB. Development of 
new drugs requires screening of large group of compounds for identification of 
suitable drug candidates. Therefore, a simple and reliable method for the 
determination of minimum inhibitory concentration (MIC) is required to determine 
the relationship between in vitro susceptibility testing and clinical test (Fabry et al., 
1996). Rapid detection and identification of mycobacterial susceptibility are 
important to control the outbreak of multiple-drug resistant strain and for the 
